Research In Brief
This article was originally published in The Gray Sheet
Executive Summary
ASTRO results
You may also be interested in...
Boston Sci Controls New Asthma Device Market With Acquisition
Boston Scientific will spend up to $443.5 million to get its hands on the first interventional device to treat asthma and, in the process, hopes to lessen its reliance on a sluggish cardiovascular franchise
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.